Sign in or create an account to add this stock to your watchlist.
About resTORbio (NASDAQ:TORC)
resTORbio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. Its lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems. The company's lead drug candidate RTB101 is a selective, orally administered, TORC1 inhibitor, which is being tested in a Phase 2b clinical trial as a first in-class immunotherapy for reducing the incidence of respiratory tract infections in the elderly by enhancing the function of the immune system. It also intends to develop RTB101 for additional aging-related indications, such as heart failure or neurodegenerative diseases. The company was founded in 2016 and is based in Boston, Massachusetts. resTORbio, Inc. is a subsidiary of PureTech Health plc.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E Ratio-1.09
Forward P/E Ratio-5.22
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$4.65 per share
Price / Book1.97
EPS (Most Recent Fiscal Year)N/A
Return on EquityN/A
Return on AssetsN/A
resTORbio (NASDAQ:TORC) Frequently Asked Questions
What is resTORbio's stock symbol?
resTORbio trades on the NASDAQ under the ticker symbol "TORC."
How were resTORbio's earnings last quarter?
resTORbio (NASDAQ:TORC) issued its quarterly earnings results on Thursday, May, 10th. The company reported ($0.46) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.26) by $0.20. View resTORbio's Earnings History.
What price target have analysts set for TORC?
4 brokerages have issued 12 month price targets for resTORbio's shares. Their forecasts range from $23.00 to $36.00. On average, they expect resTORbio's stock price to reach $29.25 in the next year. View Analyst Ratings for resTORbio.
Are investors shorting resTORbio?
resTORbio saw a increase in short interest in the month of April. As of April 13th, there was short interest totalling 786,110 shares, an increase of 28.2% from the March 30th total of 613,293 shares. Based on an average trading volume of 153,253 shares, the short-interest ratio is currently 5.1 days. Currently, 6.8% of the shares of the stock are short sold.
Who are some of resTORbio's key competitors?
Some companies that are related to resTORbio include CytomX Therapeutics (CTMX), Lexicon Pharmaceuticals (LXRX), Esperion Therapeutics (ESPR), Eagle Pharmaceuticals (EGRX), Flexion Therapeutics (FLXN), MacroGenics (MGNX), Omeros (OMER), Endocyte (ECYT), OptiNose (OPTN), Vanda Pharmaceuticals (VNDA), Amarin (AMRN), Assembly Biosciences (ASMB), NuCana (NCNA), Karyopharm Therapeutics (KPTI) and Arrowhead Pharmaceuticals (ARWR).
Who are resTORbio's key executives?
resTORbio's management team includes the folowing people:
- Mr. Chen Schor, Co-Founder, Pres, CEO & Director (Age 46)
- Dr. Joan Mannick M.D., Co-Founder & Chief Medical Officer (Age 59)
- Mr. John J. McCabe CPA, CPA, VP of Fin. & Principal Accounting Officer (Age 50)
- Dr. Abdellah Sentissi Ph.D., Head of CMC & Pharmaceutical Devel. (Age 68)
- Ms. Susan Stewart J.D., Head of Regulatory Affairs
When did resTORbio IPO?
(TORC) raised $86 million in an initial public offering on Friday, January 26th 2018. The company issued 5,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Leerink Partners and Evercore ISI acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.
Has resTORbio been receiving favorable news coverage?
News coverage about TORC stock has been trending somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. resTORbio earned a media sentiment score of 0.10 on Accern's scale. They also assigned press coverage about the company an impact score of 47.61 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are resTORbio's major shareholders?
resTORbio's stock is owned by many different of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (1.96%), Artal Group S.A. (1.60%), BlackRock Inc. (1.06%), Rock Springs Capital Management LP (0.98%), JPMorgan Chase & Co. (0.59%) and Northern Trust Corp (0.24%). Company insiders that own resTORbio stock include Chen Schor, Orbimed Advisors Llc and Puretech Health Llc. View Institutional Ownership Trends for resTORbio.
Which major investors are buying resTORbio stock?
TORC stock was purchased by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Artal Group S.A., BlackRock Inc., Rock Springs Capital Management LP, JPMorgan Chase & Co., Northern Trust Corp, Schwab Charles Investment Management Inc. and Citadel Advisors LLC. Company insiders that have bought resTORbio stock in the last two years include Chen Schor, Orbimed Advisors Llc and Puretech Health Llc. View Insider Buying and Selling for resTORbio.
How do I buy shares of resTORbio?
Shares of TORC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is resTORbio's stock price today?
One share of TORC stock can currently be purchased for approximately $9.14.
How big of a company is resTORbio?
resTORbio has a market capitalization of $256.34 million. The company earns $-33,770,000.00 in net income (profit) each year or ($8.42) on an earnings per share basis. resTORbio employs 7 workers across the globe.
How can I contact resTORbio?
resTORbio's mailing address is 500 BOYLSTON STREET 12TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at 857-315-5521.
MarketBeat Community Rating for resTORbio (TORC)MarketBeat's community ratings are surveys of what our community members think about resTORbio and other stocks. Vote "Outperform" if you believe TORC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TORC will underperform the S&P 500 over the long term. You may vote once every thirty days.
resTORbio (NASDAQ:TORC) Earnings History and Estimates Chart
resTORbio (NASDAQ:TORC) Earnings Estimates
2018 EPS Consensus Estimate: ($1.45)
2019 EPS Consensus Estimate: ($2.24)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
resTORbio (NASDAQ TORC) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
resTORbio (NASDAQ:TORC) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
resTORbio (NASDAQ TORC) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 39.25%
resTORbio (NASDAQ TORC) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|4/16/2018||Chen Schor||Insider||Buy||2,000||$8.95||$17,900.00|| |
|4/10/2018||Chen Schor||Insider||Buy||2,000||$8.46||$16,920.00|| |
|1/30/2018||Orbimed Advisors Llc||Director||Buy||533,333||$15.00||$7,999,995.00|| |
|1/30/2018||Puretech Health Llc||Major Shareholder||Buy||233,333||$15.00||$3,499,995.00|| |
resTORbio (NASDAQ TORC) News Headlines
|resTORbio (TORC) and Its Peers Head-To-Head Review|
www.americanbankingnews.com - May 26 at 7:19 PM
|resTORbio to Host Key Opinion Leader Symposium on TORC1 Inhibition|
finance.yahoo.com - May 23 at 9:13 AM
|Reviewing resTORbio (TORC) and Its Peers|
www.americanbankingnews.com - May 18 at 11:24 PM
|Zacks: Brokerages Anticipate resTORbio (TORC) to Announce -$0.42 EPS|
www.americanbankingnews.com - May 17 at 1:25 AM
| resTORbio (TORC) Receives Consensus Rating of "Strong Buy" from Analysts|
www.americanbankingnews.com - May 13 at 1:41 PM
|Head to Head Survey: Supernus Pharmaceuticals (SUPN) versus resTORbio (TORC)|
www.americanbankingnews.com - May 12 at 9:05 PM
|Critical Contrast: resTORbio (TORC) & The Competition|
www.americanbankingnews.com - May 12 at 5:11 PM
|resTORbio (TORC) Issues Earnings Results|
www.americanbankingnews.com - May 11 at 2:22 PM
|resTORbio Reports First Quarter 2018 Financial Results|
finance.yahoo.com - May 11 at 8:31 AM
|resTORbio to Present at the Bank of America Merrill Lynch 2018 Health Care Conference|
finance.yahoo.com - May 10 at 8:30 AM
|Topline 16-week data now expected in the third quarter of 2018|
globenewswire.com - May 9 at 3:24 PM
|ResTORbio completes dosing in mid-stage study of RTB101 in respiratory tract infections; data readout next quarter; shares up 4%|
seekingalpha.com - May 9 at 3:24 PM
|resTORbio Completes Dosing of Patients in Phase 2b Study to Reduce the Incidence of Respiratory Tract Infections in the Elderly|
finance.yahoo.com - May 9 at 8:38 AM
|resTORbio (TORC) & Its Competitors Head-To-Head Survey|
www.americanbankingnews.com - May 4 at 5:19 PM
|ValuEngine Upgrades resTORbio (TORC) to Hold|
www.americanbankingnews.com - May 2 at 3:48 PM
|resTORbio to Present at the Deutsche Bank 43rd Annual Health Care Conference|
finance.yahoo.com - May 2 at 8:22 AM
|resTORbio (TORC) Expected to Announce Earnings of -$0.29 Per Share|
www.americanbankingnews.com - April 29 at 11:10 AM
|Brokerages Expect resTORbio (TORC) to Post ($0.29) EPS|
www.americanbankingnews.com - April 28 at 7:52 AM
|resTORbio (TORC) Short Interest Update|
www.americanbankingnews.com - April 28 at 2:28 AM
|resTORbio (TORC) Insider Chen Schor Buys 2,000 Shares|
www.americanbankingnews.com - April 17 at 10:14 AM
|Zacks: Analysts Set $29.25 Target Price for resTORbio (TORC)|
www.americanbankingnews.com - April 13 at 3:29 AM
|Thursday 4/12 Insider Buying Report: ETM, TORC|
www.nasdaq.com - April 12 at 3:21 PM
|-$0.29 Earnings Per Share Expected for resTORbio (TORC) This Quarter|
www.americanbankingnews.com - April 12 at 1:25 PM
|BioSci Rounds Report: Improving Fundamentals To Catapult Omeros And Restorbio|
seekingalpha.com - April 12 at 7:54 AM
|Wedbush Weighs in on resTORbio's Q1 2018 Earnings (TORC)|
www.americanbankingnews.com - April 12 at 7:25 AM
|resTORbio (TORC) Insider Chen Schor Acquires 2,000 Shares|
www.americanbankingnews.com - April 11 at 10:16 AM
|resTORbio (TORC) Releases Earnings Results, Misses Estimates By $4.08 EPS|
www.americanbankingnews.com - March 30 at 9:16 AM
|resTORbio Reports Fourth Quarter and Full Year 2017 Financial Results|
finance.yahoo.com - March 30 at 7:34 AM
|A Cambridge biotech is the worst-performing IPO so far this year nationally|
finance.yahoo.com - March 29 at 3:20 PM
|Analysts Expect resTORbio, Inc. (TORC) to Announce ($1.03) Earnings Per Share|
www.americanbankingnews.com - March 29 at 10:29 AM
|resTORbio, Inc. (TORC) Expected to Post Earnings of -$1.03 Per Share|
www.americanbankingnews.com - March 26 at 1:06 PM
|resTORbio Announces Formation of Clinical Advisory Board|
finance.yahoo.com - March 19 at 3:18 PM
|Analysts Anticipate resTORbio, Inc. (TORC) to Post ($1.03) Earnings Per Share|
www.americanbankingnews.com - March 14 at 3:26 AM
|-$1.03 EPS Expected for resTORbio, Inc. (TORC) This Quarter|
www.americanbankingnews.com - March 9 at 12:45 PM
|Zacks: resTORbio, Inc. (TORC) Given Average Rating of "Strong Buy" by Brokerages|
www.americanbankingnews.com - March 8 at 3:28 AM
|Brokerages Anticipate resTORbio, Inc. (TORC) to Post ($1.03) Earnings Per Share|
www.americanbankingnews.com - March 2 at 7:16 PM
|resTORbio, Inc.'s Quiet Period Set To End on March 7th (NASDAQ:TORC)|
www.americanbankingnews.com - February 28 at 1:08 AM
|Brokerages Expect resTORbio, Inc. (TORC) to Post ($1.03) Earnings Per Share|
www.americanbankingnews.com - February 25 at 3:30 PM
|Brokers Set Expectations for resTORbio, Inc.'s FY2017 Earnings (TORC)|
www.americanbankingnews.com - February 22 at 6:46 AM
|Zacks: resTORbio, Inc. (TORC) Given $29.25 Consensus Target Price by Brokerages|
www.americanbankingnews.com - February 21 at 9:52 AM
|Four Reasons Behind BofA's Bullish Restorbio Initiation|
finance.yahoo.com - February 21 at 6:13 AM
|resTORbio (TORC) Now Covered by Evercore ISI|
www.americanbankingnews.com - February 20 at 9:30 PM
|resTORbio to Present at the 2018 RBC Capital Markets Global Healthcare Conference|
finance.yahoo.com - February 20 at 3:17 PM
|resTORbio (TORC) Earns Buy Rating from Analysts at Bank of America|
www.americanbankingnews.com - February 20 at 3:07 PM
|resTORbio (TORC) Research Coverage Started at Leerink Swann|
www.americanbankingnews.com - February 20 at 11:30 AM
|resTORbio (TORC) Now Covered by Analysts at Wedbush|
www.americanbankingnews.com - February 20 at 7:34 AM
|resTORbio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares|
finance.yahoo.com - February 5 at 8:39 AM
|Insider Buying: resTORbio, Inc. (TORC) Major Shareholder Purchases 233,333 Shares of Stock|
www.americanbankingnews.com - January 31 at 12:20 AM
|Insider Buying: resTORbio, Inc. (TORC) Director Purchases 533,333 Shares of Stock|
www.americanbankingnews.com - January 30 at 9:18 PM
|resTORbio (TORC) Announces January 26th IPO|
www.americanbankingnews.com - January 18 at 1:30 AM
resTORbio (NASDAQ:TORC) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
resTORbio (NASDAQ TORC) Stock Chart for Sunday, May, 27, 2018